• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

催乳素16千道尔顿片段在毛细血管内皮细胞上的特异性、高亲和力、可饱和结合位点。

A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells.

作者信息

Clapp C, Weiner R I

机构信息

Reproductive Endocrinology Center, University of California, San Francisco 94143.

出版信息

Endocrinology. 1992 Mar;130(3):1380-6. doi: 10.1210/endo.130.3.1311239.

DOI:10.1210/endo.130.3.1311239
PMID:1311239
Abstract

A 16-kilodalton N-terminal fragment of PRL (16K PRL) is formed by enzymatic cleavage of intact 23-kilodalton PRL (23K PRL) in the pituitary gland and in target tissues for PRL. 16K PRL inhibits the growth of capillary endothelial cells, while intact PRL was inactive suggesting that 16K PRL acted via a receptor other than the PRL receptor. To analyze whether this inhibitory effect could be mediated through an specific 16K PRL receptor, we characterized the binding of 16K PRL to membrane preparations of bovine brain capillary endothelial (BBE) cells. 16K PRL was generated by the proteolysis of rat 23K PRL with a particulate fraction from rat mammary gland homogenates and purified by gel filtration. The specific binding of [125I]16K PRL to BBE cell membranes was high affinity (Kd = 9.9 nM), saturable (Bmax = 4.8 pmol/mg protein), and reversible. In competition studies for [125I]16K PRL binding, 16K PRL was most potent, while little displacement was observed with high concentrations of 23K PRLs, growth hormones, and basic fibroblast growth factor. Blockade of reformation of disulfide bonds by carbamidomethylation of 16K PRL, a procedure which increases the biological activity of the molecule, increased its binding affinity (Kd = 0.9 nM). Cross-linking experiments identified a 52,000 and a 32,000 mol wt protein as the major 16K PRL binding species. These data demonstrate the presence of specific, high affinity, saturable binding sites for 16K PRL on BBE cell membranes and support biological findings that 16K PRL inhibits capillary endothelial cell proliferation, through a novel, high affinity receptor.

摘要

催乳素(PRL)的16千道尔顿N端片段(16K PRL)是由垂体腺和PRL靶组织中完整的23千道尔顿PRL(23K PRL)经酶切形成的。16K PRL可抑制毛细血管内皮细胞的生长,而完整的PRL则无此活性,这表明16K PRL是通过PRL受体以外的受体发挥作用的。为了分析这种抑制作用是否可通过特异性的16K PRL受体介导,我们对16K PRL与牛脑毛细血管内皮(BBE)细胞膜制剂的结合进行了表征。16K PRL是通过用大鼠乳腺匀浆的颗粒部分对大鼠23K PRL进行蛋白水解产生的,并通过凝胶过滤进行纯化。[125I]16K PRL与BBE细胞膜的特异性结合具有高亲和力(Kd = 9.9 nM)、可饱和性(Bmax = 4.8 pmol/mg蛋白)且可逆。在[125I]16K PRL结合的竞争研究中,16K PRL最有效,而高浓度的23K PRL、生长激素和碱性成纤维细胞生长因子几乎没有观察到置换作用。通过对16K PRL进行氨基甲酰甲基化来阻断二硫键的重新形成,该过程可增加分子的生物活性,同时增加了其结合亲和力(Kd = 0.9 nM)。交联实验确定了分子量为52,000和32,000的蛋白质为主要的16K PRL结合物种。这些数据证明了BBE细胞膜上存在16K PRL的特异性、高亲和力、可饱和结合位点,并支持了16K PRL通过一种新型高亲和力受体抑制毛细血管内皮细胞增殖的生物学发现。

相似文献

1
A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells.催乳素16千道尔顿片段在毛细血管内皮细胞上的特异性、高亲和力、可饱和结合位点。
Endocrinology. 1992 Mar;130(3):1380-6. doi: 10.1210/endo.130.3.1311239.
2
The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells.催乳素的16K片段特异性抑制毛细血管内皮细胞的基础生长或成纤维细胞生长因子刺激的生长。
Endocrinology. 1991 Aug;129(2):896-900. doi: 10.1210/endo-129-2-896.
3
Binding studies with intact rat prolactin and a 16K fragment of the hormone.
Endocrinology. 1989 Aug;125(2):1054-9. doi: 10.1210/endo-125-2-1054.
4
The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis.人催乳素16千道尔顿的N端片段是血管生成的强效抑制剂。
Endocrinology. 1993 Sep;133(3):1292-9. doi: 10.1210/endo.133.3.7689950.
5
Proteolysis of human prolactin: resistance to cathepsin D and formation of a nonangiostatic, C-terminal 16K fragment by thrombin.人催乳素的蛋白水解作用:对组织蛋白酶D的抗性以及凝血酶形成非血管生成性的C末端16K片段。
Endocrinology. 1999 Sep;140(9):4127-32. doi: 10.1210/endo.140.9.6955.
6
Biological and immunological characterization of cleaved and 16K forms of rat prolactin.
Endocrinology. 1988 Jun;122(6):2892-8. doi: 10.1210/endo-122-6-2892.
7
Analysis of the proteolytic cleavage of prolactin by the mammary gland and liver of the rat: characterization of the cleaved and 16K forms.
Endocrinology. 1987 Dec;121(6):2055-64. doi: 10.1210/endo-121-6-2055.
8
16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation.16K-催乳素抑制内皮型一氧化氮合酶的激活、细胞内钙动员以及内皮依赖性血管舒张。
Endocrinology. 2004 Dec;145(12):5714-22. doi: 10.1210/en.2004-0647. Epub 2004 Sep 9.
9
Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance.组织蛋白酶D将人催乳素加工成多个16K样N端片段:对其抗血管生成特性及生理相关性的研究。
Mol Endocrinol. 2004 Oct;18(10):2522-42. doi: 10.1210/me.2004-0200. Epub 2004 Jun 10.
10
The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation.抗血管生成因子16K催乳素通过激活半胱天冬酶诱导内皮细胞发生程序性细胞死亡。
Mol Endocrinol. 2000 Oct;14(10):1536-49. doi: 10.1210/mend.14.10.0543.

引用本文的文献

1
The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability.抗血管生成肽VIAN-c4551通过降低肺血管通透性抑制小鼠肺黑色素瘤转移。
PLoS One. 2025 May 28;20(5):e0316983. doi: 10.1371/journal.pone.0316983. eCollection 2025.
2
Prolactin: structure, receptors, and functions.催乳素:结构、受体与功能
Rev Endocr Metab Disord. 2024 Dec;25(6):953-966. doi: 10.1007/s11154-024-09915-8. Epub 2024 Oct 30.
3
Immunometric and functional measurement of endogenous vasoinhibin in human sera.
免疫计量法和功能性检测人血清中的内源性血管抑制素。
Front Endocrinol (Lausanne). 2024 Apr 29;15:1345996. doi: 10.3389/fendo.2024.1345996. eCollection 2024.
4
Prolactin Inhibition in Peripartum Cardiomyopathy: Systematic Review and Meta-analysis.围生期心肌病中催乳素抑制作用的系统评价和荟萃分析。
Curr Probl Cardiol. 2023 Feb;48(2):101461. doi: 10.1016/j.cpcardiol.2022.101461. Epub 2022 Oct 17.
5
Prolactin and vasoinhibin are endogenous players in diabetic retinopathy revisited.催乳素和血管抑素是糖尿病视网膜病变的内源性参与者的再探讨。
Front Endocrinol (Lausanne). 2022 Sep 9;13:994898. doi: 10.3389/fendo.2022.994898. eCollection 2022.
6
The role of prolactin/vasoinhibins in cardiovascular diseases.催乳素/血管抑制素在心血管疾病中的作用。
Animal Model Exp Med. 2023 Apr;6(2):81-91. doi: 10.1002/ame2.12264. Epub 2022 Aug 3.
7
Development of Vasoinhibin-Specific Monoclonal Antibodies.血管抑素特异性单克隆抗体的研制。
Front Endocrinol (Lausanne). 2021 Apr 20;12:645085. doi: 10.3389/fendo.2021.645085. eCollection 2021.
8
Levosulpiride Increases the Levels of Prolactin and Antiangiogenic Vasoinhibin in the Vitreous of Patients with Proliferative Diabetic Retinopathy.左舒必利可提高增殖性糖尿病视网膜病变患者玻璃体中催乳素和抗血管生成血管抑制素的水平。
Transl Vis Sci Technol. 2020 Aug 17;9(9):27. doi: 10.1167/tvst.9.9.27. eCollection 2020 Aug.
9
Vasoinhibin reduces joint inflammation, bone loss, and the angiogenesis and vasopermeability of the pannus in murine antigen-induced arthritis.血管抑肽可减轻关节炎模型鼠的关节炎症、骨质流失以及滑膜血管生成和血管通透性。
Lab Invest. 2020 Aug;100(8):1068-1079. doi: 10.1038/s41374-020-0432-5. Epub 2020 Apr 27.
10
Regulator of Angiogenesis and Vascular Function: A 2019 Update of the Vasoinhibin Nomenclature.血管生成与血管功能调节剂:2019年血管抑制素命名法更新
Front Endocrinol (Lausanne). 2019 Apr 10;10:214. doi: 10.3389/fendo.2019.00214. eCollection 2019.